Sarepta Therapeutics (SRPT) Pares Gains Following FDA Approval
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) gives up big chunk of gains following approval. Shares up 53% after trading up over 80%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- Sarepta (SRPT) volatility low into shares could have 'considerably more upside,' Barron's says
- Volatility and Volume movement
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!